Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Buy

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Intellia Therapeutics, Inc (NTLA)

In Vitro & In Vivo Diagnostic Substances

https://www.intelliatx.com

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

40 ERIE STREET, SUITE 130
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/06/2016

Market Cap

2,262,164,330

Shares Outstanding

89,560,000

Weighted SO

89,554,891

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

EDIT --.--%

CRBU --.--%

CRSP --.--%

VERV --.--%

BEAM --.--%

FATE --.--%

VRTX --.--%

DNA --.--%

PRME --.--%

Beta

1.8110

Last Div

0.0000

Range

19.37-39.01

Chg

-0.6000

Avg Vol

1668238

Mkt Cap

2262164330

Exch

NASDAQ

Country

US

Phone

857 285 6200

DCF Diff

27.5386

DCF

-5.2136

Div Yield

0.0000

P/S

49.2128

EV Multiple

-4.3325

P/FV

2.2240

Div Yield %

0.0000

P/E

-4.2446

PEG

-0.9018

Payout

0.0000

Current Ratio

7.2054

Quick Ratio

7.2054

Cash Ratio

1.2451

DSO

97.8982

DIO

0.0000

Op Cycle

97.8982

DPO

696.0413

CCC

-598.1432

Gross Margin

0.7853

Op Margin

-11.4005

Pretax Margin

-11.0687

Net Margin

-11.0687

Eff Tax Rate

-0.0552

ROA

-0.4270

ROE

-0.4970

ROCE

-0.4823

NI/EBT

1.0000

EBT/EBIT

0.9709

EBIT/Rev

-11.4005

Debt Ratio

0.0892

D/E

0.1095

LT Debt/Cap

0.0825

Total Debt/Cap

0.0987

Int Coverage

-59.3348

CF/Debt

-3.5118

Equity Multi

1.2270

Rec Turnover

3.7284

Pay Turnover

0.5244

Inv Turnover

0.0000

FA Turnover

0.3388

Asset Turnover

0.0386

OCF/Share

-3.8493

FCF/Share

-3.9459

Cash/Share

7.1262

OCF/Sales

-8.1207

FCF/OCF

1.0251

CF Coverage

-3.5118

ST Coverage

-19.6848

CapEx Coverage

-39.8381

Div&CapEx Cov

-39.8381

P/BV

2.2240

P/B

2.2240

P/S

49.2128

P/E

-4.2446

P/FCF

-5.9118

P/OCF

-5.7855

P/CF

-5.7855

PEG

-0.9018

P/S

49.2128

EV Multiple

-4.3325

P/FV

2.2240

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 23, 01:00 INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm GlobeNewswire Inc. Apr 12, 15:43 ????? ???? ????? ?????? ??? NTLA: ????, ???????? ????, ????? ?? ?????? Intellia Therapeutics, Inc ?? ?????? ?????? ?? 100 ??? ????, ?????? ????? ???? ????? ?????? ????? ?? 14 ?????? ?????? ??????? ??????? ??? – NTLA GlobeNewswire Inc. Apr 12, 15:43 NTLA DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action – NTLA GlobeNewswire Inc. Apr 12, 15:11 ????? ?????? ?????? ??? MRK ???? ???: ????, ?????? ??????? ?????????, ????? ?? ?????? Merck & Co., Inc. ?? ?????? ?? ???? ?-100 ??? ???? ?????? ????? ???? ????? ?????? ????? ?? 14 ?????? ?????? ??????? ??????? ??? – MRK GlobeNewswire Inc. Apr 12, 15:02 ???? ????? ???? ?????? ??? TTD: ????, ???????? ?????, ??????? ?? ?????? The Trade Desk, Inc. ?? ?????? ?? ???? ?- 100 ??? ????, ?????? ????? ???? ????? ?????? ????? ?? 21 ?????? ?????? ??????? ??????? ??? – TTD GlobeNewswire Inc. Apr 10, 22:34 Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 14, 2025 Deadline to file Lead Plaintiff Motion GlobeNewswire Inc. Apr 09, 22:30 NTLA DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action – NTLA GlobeNewswire Inc. Apr 04, 20:56 NTLA DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action – NTLA GlobeNewswire Inc. Mar 29, 18:52 ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA GlobeNewswire Inc. Mar 20, 21:41 ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA GlobeNewswire Inc. Mar 16, 16:09 ????, ???? ????? ??? ???? ?????, ????? ?? ?????? Intellia Therapeutics, Inc ???? ????? ???? ????? ??? ???? ?????? ??????? ??????? ??? – NTLA GlobeNewswire Inc. Mar 14, 00:36 ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA GlobeNewswire Inc. Mar 09, 19:39 ROSEN, A LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA GlobeNewswire Inc. Feb 21, 22:43 ROSEN, LEADING INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA Benzinga Feb 19, 00:04 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA GlobeNewswire Inc. Feb 16, 03:09 ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA GlobeNewswire Inc. Feb 14, 01:27 Intellia Therapeutics, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against NTLA GlobeNewswire Inc. Nov 16, 15:16 Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis The Motley Fool Oct 24, 23:22 Why Intellia Therapeutics Stock Plummeted by 20% Today Investing.com Jul 06, 00:48 Cathie Wood's ARK buys Intellia stock, sells Tesla and Verve By Investing.com - Investing.com Australia

Revenue Product Segmentation